The products purchased through the Strategic Fund meet international safety, efficacy, and qualityguidelines and standards. Products not included in this list (such as diagnostics and equipment for TB, HPV, Opportunistic Infections, Chagas, and Leishmaniasis, among others) can be purchased upon request by Member States.
Using the slicers at the top of the visual, you can search for a specific product and filter the table by category, disease area, and indication.
Download the product list and prices in PDF:
The Strategic Fund Medicine List does not seek to replace or complement the WHO Essential Medicine List or Member States’ national essential medicine lists. As a result, it should not be utilized as a reference for the development of other essential medicine lists or treatment guidelines.
Prices and lead time will depend on product availability at the time of the request. Prices are listed with FCA Incoterm and are not guaranteed and do not constitute a formal price proposal. For budgeting purposes, PAHO suggests that the Member States add 20-25% to reflect the cost of freight and insurance to the port of delivery and a 4.25% surcharge on the product price.
Upon request of Member States, certain products not on the List, such as diagnostics and equipment for TB, HPV, Opportunistic Infections, Chagas, and Leishmaniasis, among others, may be available through PAHO.